首頁 > 市場調查報告書 > 製藥

非專利藥

市場調查報告書

商品編碼

1793487

學名藥的全球市場:適應症 (中樞神經系統·循環系統·泌尿系統·腫瘤·呼吸系統·其他)·給藥途徑·流通管道·各地區 (～2035年)

Global Generic Drugs Market Research Report by Indication (Central Nervous System, Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration, by Distribution Channel, and by Region Forecast till 2035

出版日期: 2025年07月08日 | 出版商:

Market Research Future | 英文 143 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

預計到 2035 年，全球仿製藥市場規模將成長兩倍，年均成長率穩定在 9.36%，達到 11,485.5 億美元。

慢性病的增多是全球仿製藥市場成長的主要推動因素。癌症、心臟病、癲癇和關節炎等疾病的快速增長催生了對平價治療的需求。仿製藥能夠以更低的價格提供與品牌藥相同的治療效果，有時是精打細算的患者和醫療保健系統的唯一選擇。市場參與者正在透過推出新產品、擴大現有設施以及拓展新的治療領域來加強其供應。

另一方面，由於品質和安全問題而導致的產品自願召回仍然是仿製藥產品供應和信任度下降的主要障礙。此外，醫護人員對品牌藥的忠誠度也限制了仿製藥的採用，導致許多人繼續開立熟悉的品牌藥。

同時，研發投入促進了高品質仿製藥的生產，從而帶來了尖端技術的引進和市場擴張。全球老化也是一個關鍵因素，老年人佔了相當大的市場佔有率，支撐著對慢性病治療的需求。預計到2050年，亞太地區老年人口將翻一番，提供價格實惠的藥品將成為當務之急。這些趨勢，加上政府的支持性政策，很可能將確保仿製藥在全球醫療保健服務中繼續佔領先地位。

區域分析

在北美，抑制醫療成本上漲的需求支撐了仿製藥市場。美國憑藉其廣泛的製造網絡和清晰的法律框架（允許專利到期和仿製藥替代）成為區域領導者。患者對仿製藥的接受度正在不斷提高，這支撐了強勁的銷售業績，尤其是在心臟病學、腫瘤學和抗生素領域。加拿大強調成本效益的醫療政策也穩步支持仿製藥的廣泛採用。

歐洲市場受益於清晰的監管環境和公共醫療體系對低價的重視。德國、西班牙和英國是主要的消費國，各國的醫療保健服務都鼓勵仿製藥的處方。東歐國家藥品可及性的提高和中產階級人口的成長正在推動仿製藥的需求。具有競爭力的價格和支援性的法律框架正在推動區域成長。

亞太地區是成長最快的地區，這在很大程度上得益於印度和中國的製造能力。印度在以最合理的價格供應高品質仿製藥方面處於全球領先地位，而中國也受益於重大的醫療改革。人口結構變化和慢性病發病率上升推動了對平價藥品的需求。包括韓國和泰國在內的越來越多的國家正在積極使用仿製藥來降低醫療成本。本報告探討了全球仿製藥市場，並提供了市場定義和概述、影響市場成長的各種因素分析、市場規模趨勢和預測、按細分市場、地區和主要國家/地區進行的細分、競爭格局以及主要公司的概況。

Global Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035

Industry Overview

The global generic drugs market is expected to nearly triple to USD 1,148.55 billion by 2035, driven by steady annual growth of 9.36%. A generic drug is a pharmaceutical product equivalent in dosage, strength, safety, and intended use to a branded medicine but sold under its chemical name. These drugs are typically marketed after patent protection ends, making them a cost-effective option for patients and healthcare systems.

The prevalence of chronic illnesses has been identified as a significant factor contributing to the growth of the global generic medication market. Cancer, heart disease, and other conditions like these have increased dramatically, and this is the case with the rise of epilepsy and arthritis, resulting in the need for low-cost treatment. Generic medicines deliver therapeutic benefits similar to those of branded drugs but at a much lower price; therefore, they become the only option for patients and healthcare systems that face difficult situations with their budgets. The players of the market are intensifying their supply by launching new products, extending their existing facilities, and entering into new therapeutic areas.

Nevertheless, voluntary product recalls caused by quality or safety issues remain a major obstacle to the availability of products and confidence in generics. Brand loyalty of healthcare professionals is one of the factors that limits wider adoption. Those who have not changed their minds still continue prescribing the branded medicines that they are familiar with to the patients.

At the same time, the act of allocating money to R&D allows the production of high-quality generics, which includes the implementation of advanced technology and the expansion of the market reach. The increasing age of the world population is one of the key factors that pushes up senior consumers, who make up a large portion of the market for chronic disease medication. By 2050, the old people in the Asia-Pacific is expected to be twice as many as they are now; therefore, affordable medicines will be the topmost issue. If these trends, combined with favorable government policies, continue to prevail, generic drugs will remain at the forefront of providing global healthcare.

Industry Segmentations

In terms of indication, the global drugs market is segmented into central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others.

The global market is classified based on the route of administration, comprising oral, topical, parenteral, and others.

Depending on the distribution channel, the global generic drug market is divided into hospital, retail, and online pharmacy.

Regional Analysis

In North America, the generic drugs market is bolstered by the need to control rising healthcare costs. The US is the leader in the region with a vast network of manufacturers and a legal framework that is clearly defined and enables patent expiry and generic substitution. Patient acceptance of generics, which is growing, has made it possible to keep a strong sales record, especially in cardiovascular, oncology, and antibiotic segments. Canadian healthcare policies that promote cost efficiency are hence one of the factors that allow generics to be steadily taken up.

Europe's market is reaping the benefits from a regulatory environment that is clear and the presence of a strong public healthcare system that emphasizes affordability. Germany, Spain, and the UK are among the top consumers of this product, and their national health services are promoting generic prescriptions. The improvement in medicine accessibility, along with the increasing numbers of the middle-class population, are the main factors driving the catching up of Eastern European countries. Competitive pricing and supportive legislation are key growth factors in the region.

Asia-Pacific is the fastest-growing region, and most of the growth is coming from the manufacturing potential of Asia, particularly India and China. India is a global leader in supplying the highest quality generics at the most reasonable prices, and China's market is receiving the positive impact of healthcare reforms on a large scale. Due to demographic changes in the age structure of the population and rising prevalence of chronic diseases, the demand for cheap drugs has increased. Besides South Korea and Thailand, these countries are also among the most prolific users of generic medicine to reduce the cost of healthcare.

Latin America, the Middle East, and Africa are an increasing part of the generic medicines market on a global scale. With Brazil, there is a more aggressive push to increase local production, while Mexico benefits from cross-border trade with the US. Rising investment in pharmaceutical manufacturing in the Middle East is contributing to the region's effort to become more self-sufficient. African countries are setting the availability of drugs and the strengthening of distribution channels for generics as their top priorities.

Key Players

Major players in the global generic drugs market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Sun Pharmaceuticals Industries, Fresenius Kabi, Lupin Pharmaceuticals, Inc., Endo International plc, Aurobindo Pharma, Aspen Holdings, Cipla Ltd., and Fresenius SE & Co. KGaA.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
- 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
- 4.2.3 RISING DEMAND FOR AFFORDABLE MEDICATIONS
4.3 RESTRAINTS
- 4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
- 4.3.2 BRAND LOYALTY AND DOCTOR PREFERENCES
4.4 OPPORTUNITY
- 4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE
- 4.4.2 RISING AGING POPULATION

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET

6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

6.1 OVERVIEW
6.2 CENTRAL NERVOUS SYSTEM (CNS)
6.3 CARDIOVASCULAR
6.4 UROLOGY
6.5 ONCOLOGY
6.6 RESPIRATORY
6.7 OTHERS

7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

7.1 OVERVIEW
7.2 ORAL
7.3 TOPICAL
7.4 PARENTERAL
7.5 OTHERS

8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

8.1 OVERVIEW
8.2 HOSPITAL PHARMACY
8.3 RETAIL PHARMACY
8.4 ONLINE PHARMACY

9 GLOBAL GENERIC DRUGS MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2024
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH
- 10.6.2 PRODUCT LAUNCH / PRODUCT APPROVAL
- 10.6.3 EXPANSION

11 COMPANY PROFILES

11.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 LUPIN PHARMACEUTICALS, INC.
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 ENDO INTERNATIONAL PLC
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 AUROBINDO PHARMA
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 ASPEN HOLDINGS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 CIPLA LTD
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 NOVARTIS AG
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 FRESENIUS SE & CO. KGAA
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 VIATRIS INC.
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 DATA CITATIONS

簡介目錄圖表

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 3 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019-2035 (USD BILLION)
TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019-2035 (USD BILLION)
TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019-2035 (USD BILLION)
TABLE 6 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019-2035 (USD BILLION)
TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019-2035 (USD BILLION)
TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019-2035 (USD BILLION)
TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019-2035 (USD BILLION)
TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019-2035 (USD BILLION)
TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
TABLE 14 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019-2035 (USD BILLION)
TABLE 16 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019-2035 (USD BILLION)
TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2035 (USD BILLION)
TABLE 18 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019-2035 (USD BILLION)
TABLE 19 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 23 US GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 24 US GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 25 US GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 26 CANADA GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 27 CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 28 CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 29 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 30 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 31 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 32 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 33 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 34 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 35 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 36 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 37 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 38 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 39 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 40 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 41 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 42 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 43 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 44 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 45 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 46 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 47 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 48 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 49 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 50 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 51 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 52 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 53 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 54 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 55 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 56 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 57 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 58 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 59 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 60 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 61 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 62 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 63 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 64 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 65 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 66 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 67 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 68 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 69 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 70 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 71 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 72 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 73 REST OF THE WORLD: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 74 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 75 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 76 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 77 MIDDLE EAST: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 78 MIDDLE EAST: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 79 MIDDLE EAST: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 80 AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 81 AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 82 AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 83 SOUTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 84 SOUTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 85 SOUTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 86 PUBLIC PLAYERS STOCK SUMMARY
TABLE 87 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 88 PRODUCT LAUNCH
TABLE 89 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 90 EXPANSION
TABLE 91 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 93 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED
TABLE 94 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
TABLE 95 ENDO INTERNATIONAL PLC: PRODUCT OFFERED
TABLE 96 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS
TABLE 97 AUROBINDO PHARMA: PRODUCT OFFERED
TABLE 98 AUROBINDO PHARMA: KEY DEVELOPMENTS
TABLE 99 ASPEN HOLDINGS: PRODUCT OFFERED
TABLE 100 CIPLA LTD.: PRODUCTS OFFERED
TABLE 101 CIPLA LTD.: KEY DEVELOPMENTS
TABLE 102 NOVARTIS AG: PRODUCTS OFFERED
TABLE 103 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 104 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED
TABLE 105 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 106 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED
TABLE 107 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS
TABLE 108 VIATRIS INC.: PRODUCT OFFERED
TABLE 109 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE
FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET
FIGURE 6 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2024 & 2035 (USD BILLION)
FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2024
FIGURE 9 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION)
FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024
FIGURE 12 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION)
FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
FIGURE 15 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019 & 2035 (USD BILLION)
FIGURE 16 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2024
FIGURE 17 NORTH AMERICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2035 (USD BILLION)
FIGURE 18 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 19 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2024
FIGURE 20 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 21 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 22 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 23 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 24 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 25 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 26 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2024
FIGURE 27 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET
FIGURE 28 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 32 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 CIPLA LTD.: FINANCIAL OVERVIEW
FIGURE 36 CIPLA LTD.: SWOT ANALYSIS
FIGURE 37 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 NOVARTIS AG: SWOT ANALYSIS
FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 41 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT